Lee Joohee, Cho Young Seok, Kim Jhingook, Shim Young Mog, Lee Kyung-Han, Choi Joon Young
Department of Nuclear Medicine, CHA Ilsan Medical Center, CHA University, Goyang 10414, Korea.
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Cancers (Basel). 2021 Feb 9;13(4):712. doi: 10.3390/cancers13040712.
Imaging tumor FDG avidity could complement prognostic implication in thymic epithelial tumors. We thus investigated the prognostic value of volume-based F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/CT parameters in thymic epithelial tumors with other clinical prognostic factors.
This is a retrospective study that included 83 patients who were diagnosed with thymic epithelial tumors and underwent pretreatment F-FDG PET/CT. PET parameters, including maximum and average standardized uptake values (SUV, SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured with a threshold of SUV 2.5. Univariate and multivariate analysis of PET parameters and clinicopathologic variables for time-to-progression was performed by using a Cox proportional hazard regression model.
There were 21 low-risk thymomas (25.3%), 27 high-risk thymomas (32.5%), and 35 thymic carcinomas (42.2%). Recurrence or disease progression occurred in 24 patients (28.9%). On univariate analysis, Masaoka stage ( < 0.001); histologic types ( = 0.009); treatment modality ( = 0.001); and SUV, SUV, MTV, and TLG (all < 0.001) were significant prognostic factors. SUV ( < 0.001) and Masaoka stage ( = 0.001) were independent prognostic factors on multivariate analysis.
SUV and Masaoka stage are independent prognostic factors in thymic epithelial tumors.
成像肿瘤的氟代脱氧葡萄糖（FDG）摄取情况可补充胸腺瘤上皮性肿瘤的预后信息。因此，我们研究了基于体积的氟-氟代脱氧葡萄糖（F-FDG）正电子发射断层扫描（PET）/CT参数在胸腺瘤上皮性肿瘤中的预后价值，并将其与其他临床预后因素进行对比。
这是一项回顾性研究，纳入了83例被诊断为胸腺瘤上皮性肿瘤且在治疗前接受F-FDG PET/CT检查的患者。PET参数，包括最大和平均标准化摄取值（SUVmax、SUVavg）、代谢肿瘤体积（MTV）和总病变糖酵解（TLG），均以SUV 2.5为阈值进行测量。采用Cox比例风险回归模型对PET参数和临床病理变量进行单因素和多因素分析，以评估疾病进展时间。
共有21例低风险胸腺瘤（25.3%）、27例高风险胸腺瘤（32.5%）和35例胸腺癌（42.2%）。24例患者（28.9%）出现复发或疾病进展。单因素分析显示，Masaoka分期（<0.001）、组织学类型（=0.009）、治疗方式（=0.001）以及SUVmax、SUVavg、MTV和TLG（均<0.001）是显著的预后因素。多因素分析显示，SUVmax（<0.001）和Masaoka分期（=0.001）是独立的预后因素。
SUVmax和Masaoka分期是胸腺瘤上皮性肿瘤的独立预后因素。
Zotero 插件